克拉斯
胰腺癌
癌症研究
医学
联合疗法
受体酪氨酸激酶
后天抵抗
突变体
酪氨酸激酶抑制剂
靶向治疗
突变
癌症
肿瘤科
MEK抑制剂
PI3K/AKT/mTOR通路
抗药性
临床试验
酪氨酸激酶
腺癌
药理学
内科学
生物
MAPK/ERK通路
激酶
胰腺
作者
Ida Aronchik,Sumit Kar,Yongxian Zhuang,Ethan Ahler,Lo Lai,Vidya Seshadri,Yu Chi Yang,Ashenafi Shiferaw Bulle,Marie Ménard,Biswadeep Nayak,Mark P. Labrecque,Julien Dilly,Eejung Kim,Lingyan Jiang,Jason K. Yano,Urszula N. Wasko,Ciara Helland,Sean Bredeson,Brett Garrick,Yevgeniy Gindin
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2026-08-01
卷期号:32 (8): 2865-2877
被引量:32
标识
DOI:10.1038/s41591-026-04537-w
摘要
Daraxonrasib is an orally bioavailable RAS(ON) multi-selective tri-complex inhibitor of the oncogenic mutant and wild-type variants of N, H and KRAS. We previously reported encouraging efficacy in a phase 1/2 clinical trial evaluating daraxonrasib monotherapy at clinically active dose levels in patients with previously treated, RAS mutant metastatic pancreatic adenocarcinoma (PDAC), providing the basis for confirmatory evaluation in the randomized phase 3 RASolute 302 clinical trial. Here we report mechanisms of acquired resistance to daraxonrasib monotherapy observed through targeted sequencing of over 800 genes in paired pretreatment and end of treatment circulating tumor DNA samples from 44 patients in the phase 1/2 clinical trial. Treatment-emergent genomic alterations in the RAS signaling pathway were observed in more than half (26 of 44; 59%) of these patients, including, most notably, mutant KRAS amplifications in one-third (16 of 44; 36%), as well as alterations in receptor tyrosine kinase (RTK) (4 of 44; 9%), MAPK (11 of 44; 25%) and PI3K (4 of 44; 9%) pathways. Notably, no acquired secondary KRAS mutations were observed, distinct from resistance profiles of mutant-selective KRAS G12C(OFF) inhibitors. To corroborate these clinical findings, we found, or mechanistically established, concordant mechanisms of daraxonrasib resistance in human and murine preclinical models of PDAC, including mutant KRAS and MYC amplification and RTK upregulation, with these alterations guiding various combination therapy concepts. Notably, daraxonrasib combined with agents targeting DNA damage response, RTKs or the mutant-selective RAS(ON) G12D inhibitor zoldonrasib averted resistance in preclinical models. Collectively, these results show that most daraxonrasib genomic resistance mechanisms drive reactivation of RAS pathway signaling and guide potential combination strategies in PDAC for further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI